From the monitoring of Bcr/Abl fusion gene level in patient with chronic myeloid leukemia to the imatinib resistance detection – case report
Authors:
P. Rohoň 1; E. Faber 1; J. Naušová 2; R. Solná 2; Š. Rožmanová 1; R. Plachý 1; M. Brejcha 3; M. Jarošová 1; V. Divoký 2; K. Indrák 1
Authors‘ workplace:
Hemato-onkologická klinika FN Olomouc a LF UP v Olomouci
1; Ústav biologie LF UP v Olomouci
2; Onkologické centrum J. G. Mendela, Nový Jičín
3
Published in:
Transfuze Hematol. dnes,13, 2007, No. 1, p. 27-31.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
There is the case report of 63-years old patient with Ph1 positive chronic myeloid leukaemia (CML) who is treated with 400 mg of imatinib daily. It is because of the secondary cytogenetic resistance to interferon alpha after two years from diagnosis. After initial cytogenetic response (10 % Bcr/Abl positive cells detected by bone marrow interphase FISH examination after 3 months and 1 log decrease in quantitative RT-PCR after 6month of treatment) there is the cytogenetic progression in one year with failure of the response to the escalated dosage 800 mg daily. It leads to the suspicion of imatinib resistance. In vitro tests confirm it: there is a high expression of WT1 gene, the presence of phosphorylated CRKL and detection of T315I mutation in Abl kinase domain. This article is aimed at detection of imatinib resistance in case of suspicion and should also show the review of the new treatment modalities. The resistance detection is important from clinical point of view. It allows to stop the therapy which is not useful and economically demanding, on the other side it moves it to the application of the new tyrosine kinase inhibitors, allogenic stem cell transplantation or to experimental treatment.
Key words:
Bcr/Abl fusion gene, WT1 gene, quantitative RT-PCR, tyrosine kinase inhibitors, T315I mutation
Sources
1. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia, Blood 2000; 96(10): 3343–3356.
2. Deininger MWN, Druker BJ. Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib, Pharmacol Rev 2003; (55): 401–423.
3. Moravcová J, Brdička R. Deset let molekulárního monitorování chronické myeloidní leukémie metodou kvantitativní RT-PCR. Čas Lék čes 2005; 144: 32–37.
4. Trka J, Kalinová M, Hrušák O, Zuna J, Krejčí O, Madžo J, Sedláček P, Vávra V, Michalová K, Jarošová M, Starý J. Czech Paediatric Haematology Working Group Real-Time Quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry, Leukemia 2002; 16(7):1381–1389.
5. Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I, Carturan S, Messa E, Morotti A, Giugliano A, Rege-Cambrin G, Alberti D, Baccarani M, Saglio G. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation, Cancer 2004; 101(5): 979–988.
6. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of „real-time“ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program. Leukemia 2003; 17: 2318–2357.
7. Naušová J, Priwitzerová M, Jarošová M, Indrák K, Faber E, Divoký V. Chronická myeloidní leukemie – rezistence na imatinib mesylát (Glivec®) – přehled literatury a vlastní zkušenosti.
8. Baccarani M, Saglio G, Goldman JM, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006 May 18; [Epub ahead of print] PMID: 16709930.
9. Simonsson B. On behalf of the IRIS (International Randomized IFN vs STI571) Study Group. Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): update from the IRIS study. Blood 2005; 106: 166.
10. Christophe BP, Reiffers VM, Mahon FX. Roots of Clinical Resistance to STI-571 Cancer 2001; 293: 2163.
11. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; (305):399–401.
12. Faber E. Dasatinib. Farmakoterapie 2006; 2: 135–137.
13. O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505.
14. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7:129–141.
15. Kantarjian H, Ottmann O, Cortes J, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML). J Clin Oncol 2005; 16: 195.
16. Mayerhofer M, Aichberger KJ, Florian S, Krauth M, Hauswirth A, Derdak S, Sperr W, Esterbauer H, Wagner O, Marosi CH, Pickl W, Deininger M, Weisberg E, Druker BJ, Griffin JD, Sillaber C, Valent P. Identification of mTOR as a novelbifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells, The FASEB Journal ExpressArticledoi:10.1096/fj.04-1973 fje Published online March 22, 2005.
17. Matthew A. Young, Neil P. Shah, Luke H. Chao, Markus Seeliger, Zdravko V. Milanov, William H. Biggs, III, Daniel K. Treiber, Hitesh K. Patel, Patrick P. Zarrinkar, David J. Lockhart, Charles L. Sawyers, John Kuriyan. Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680. Cancer Research 2006, 1007–1014.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2007 Issue 1
Most read in this issue
- Results and complications of splenectomy in patients with severe thrombocytopenia in ITP resistant to initial conservative therapy – centre experience
- A relationship of serum imunoglobulin free light chain levels measurement to multiple myeloma staging
- From the monitoring of Bcr/Abl fusion gene level in patient with chronic myeloid leukemia to the imatinib resistance detection – case report
- Therapy of follicular lymphoma - latest developments